Roots of New Drug for HES Trace Back to Cincinnati Children’s

Post Date: September 29, 2020


Marc Rothenberg, MD, PhD

In 2008, Marc Rothenberg, MD, PhD, Director of the Division of Allergy and Immunology and the Cincinnati Center for Eosinophilic Disorders at Cincinnati Children’s, led an international group of investigators to conduct a randomized clinical trial that proved the ability of mepolizumab to lower oral steroid doses in patients with HES.

Read more about the FDA’s approval of mepolizumab

About this blog

The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.